89bio, Inc. is a top healthcare stock to buy, focusing on therapies for liver and cardiometabolic diseases like MASH. Roche plans to acquire 89bio for $2.4 billion, with a potential total deal value of $3.5 billion based on pegozafermin’s success. The acquisition is expected to close in Q4 2025.

Roche aims to integrate pegozafermin into its portfolio to maximize its impact on cardiovascular, renal, and metabolic conditions. This strategic move follows strong confidence in pegozafermin’s potential as a best-in-class therapy for MASH. The transaction is set to close in Q4 2025, pending board approval.

While 89bio shows promise as an investment, some AI stocks might offer greater upside potential with lower downside risk. Consider exploring undervalued AI stocks poised to benefit from current economic trends. For more insights, check out our report on the best short-term AI stock.

Read more at Yahoo Finance: 89bio, Inc. (ETNB) Shareholders to Receive Up to $3.5B Total in Roche Buyout Deal